In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
about
Current and emerging azole antifungal agentsMelanized fungi in human diseaseIn vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin BEfficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosisIn vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungiIn vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.Madurella mycetomatis is highly susceptible to ravuconazoleOptimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole.Efficacy of ravuconazole in treatment of mucosal candidosis in SCID miceIn vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.Resistance to antifungals that target CYP51.Benzimidazole-1,2,3-triazole hybrid molecules: synthesis and evaluation for antibacterial/antifungal activity.In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans4-{4-[(4-Oxoquinazolin-3-yl)meth-yl]-1H-1,2,3-triazol-1-yl}butyl acetate.In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.Advances in synthetic approach to and antifungal activity of triazoles.Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study
P2860
Q24550733-57E7793F-BF87-48D8-97B3-52EF6599CA99Q24633163-B7B055A6-224E-44BE-88CA-32FB0F48AD11Q28343867-FFFC66EB-0107-4848-AB04-C594DEE345BCQ28344947-2816F8C4-F7E2-4644-A80E-575B58E7E7AEQ28355507-3EAC66A5-696C-410F-97D1-1414EC01DBDBQ28369323-CEAC2DA1-D7A7-4174-86B6-E9C3DD7E64D2Q28539848-7BA6D1D6-3689-43C1-B74E-9190345272A8Q30453651-0DD2BB7F-44C5-4B00-9F45-2A1F7458D04EQ30453666-A6E145A4-12C4-48BA-BFD8-6BF7BCD4A466Q31033645-27BF446A-1341-4925-BE4A-C7F64EC248C5Q33981488-74C9D7EC-8929-48B6-A716-219908B3BC21Q33983594-B2310E36-4CEE-4D19-9CEC-060815C5A746Q34109559-69F5CECB-48C7-40B3-9060-AF949752BF51Q34113955-CACAC914-1676-4E20-9866-61290415FF41Q34144184-0334AD99-20CD-42FB-94A0-7462DA29F886Q34195380-B649FF0A-575A-4367-A4A9-DCC18CADEB3DQ34202213-9675BB66-0E4A-440C-B044-26204559B32DQ34276700-0820E891-77C3-4084-A6D8-B16DEE9FAFCCQ34477591-E5EDDFC5-3E6F-4BF3-B470-F4C4C7C49FE3Q36669593-07536E3A-1DBF-44E9-8C79-7EC688B4CA2BQ37119029-81169997-0012-4947-8152-95BF2CD955E0Q39475482-F6F4CD4A-F130-4773-A1F5-4977FCD448D4Q39816795-471EF300-777C-4917-B61E-F0136C918B6BQ40668115-D6C62032-C3ED-451B-BD26-4EFED441E30BQ42206400-EFCF9464-E181-44EC-8A68-6503FF94C4EBQ58697730-63056DE8-73ED-446B-9B4F-BD00BF96431E
P2860
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@ast
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@en
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@nl
type
label
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@ast
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@en
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@nl
prefLabel
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@ast
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@en
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@nl
P2093
P2860
P1476
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
@en
P2093
B Minassian
D P Bonner
J C Fung-Tomc
P2860
P407
P577
1998-02-01T00:00:00Z